Merck and Eisai report mixed results from LEAP-015 trial of Keytruda and Lenvima in HER2-negative gastroesophageal cancer treatment.

Apple stock cracks 11% YTD to test key technical level, emerges worst Magnificent Seven performer since new year ...

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

Anavex Life Sciences' Blarcamesine trial raises concerns over approval. Learn why AVXL stock is undervalued, reflecting the low probability of success.

Thomas Trutschel / Photothek via Getty Images Neumora Therapeutics reported ... navacaprant treatment failed to reach both primary and secondary endpoints. The company said it would continue ...

Labrador, Canada The Double Mer Uranium Project is SAGA Metals' flagship project, covering 1,024 claims across 25,600 ...

Psilocybin-assisted therapy induced positive personality changes in adults with alcohol use disorder, which may help to ...

Integrating lifestyle care into low back pain management resulted in greater improvements in disability, weight loss and physical quality of life vs. just guideline-recommended care, a randomized ...

It is not a comprehensive analysis of a full-year outlook. Nvidia was the most remarkable technology story of 2024 — both in ...

Partners from Latham, Proskauer, Kirkland, Morrison Foerster and Skadden say they are optimistic about 2025, citing activity ...

Denali Therapeutics Inc. DNLI announced disappointing top-line results from an analysis of Regimen G of the phase II/III HEALEY ALS Platform Trial on pipeline candidate DNL343. The HEALEY platform ...